Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, announced that Sean Martin has been named the company’s Chief Legal Officer and General Counsel, overseeing all legal and compliance matters.
Mr. Martin brings deep corporate and commercial healthcare experience to Generate. For the past five years, he was General Counsel and Senior Vice President at Baxter International Inc., a leading global healthcare company that provides products, digital health solutions, and therapies in more than 100 countries. Under his leadership, Mr. Martin successfully managed the legal, compliance, and government affairs matters for several key projects including the largest acquisition in Baxter’s history, Hillrom, Inc., and a restatement of some of the company’s financial results for several previous years following a self-disclosure to the Securities and Exchange Commission.
Before that role, he was General Counsel, Senior Vice President and Secretary at Apollo Education Group, the parent company of the for-profit University of Phoenix, which was sold to Apollo Global Management in 2017. Previously, he was Vice President for Commercial Law and Corporate Law at Amgen, and Vice President and Deputy General Counsel for Litigation at Fresenius Medical Care North America, a renal care company. Earlier in his career, Mr. Martin was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases.
“We’re delighted that Sean is joining the Generate Biomedicines team given his exemplary track record in global healthcare and broader business leadership. His impressive experience in intellectual property creation and expansion, corporate partnerships and transactions, and crucial legal, ethics, and compliance matters will help propel our growth as we pioneer the field of generative biology,” said Mike Nally, Generate’s Chief Executive Officer.
Mr. Martin commented, “I am thrilled to be joining Generate at such an exciting time. With its $370 million Series B funding, partnership with Amgen, and significant advances in the company’s generative biology platform, the company is poised to revolutionize drug development through computer-designed protein therapeutics for potentially any disease target.”
Mr. Martin graduated summa cum laude from the University of Michigan with a bachelor’s degree in history and graduated magna cum laude from the Harvard Law School.